Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-γ

Stem Cells

Volumn 24, Issue 11, 2006, Pages 2466-2477

  Chang, Chun Jung ^a   Yen, Men Luh ^b   Chen, Yao Chang ^b   Chien, Chih Cheng ^c,d   Huang, Hsing I ^c,e   Bai, Chyi Huey ^f   Yen, B Linju ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d Cathay General Hospital Neihu   (United States)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

^f SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Human leukocyte antigen, class I, G; Immunosuppression; Indoleamine 2,3 dioxygenase; Mesenchymal stem cell; Mixed lymphocyte culture interferon ; Multilineage differentiation; Placenta

Indexed keywords

2,3 DIOXYGENASE; GAMMA INTERFERON; HLA G ANTIGEN; MITOGENIC AGENT; OXYGENASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CD4 CD8 RATIO; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MULTIPOTENT STEM CELL; PLACENTA; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

BONE MARROW CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-10; ISOANTIGENS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELLS; MITOGENS; MULTIPOTENT STEM CELLS; PLACENTA; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 33750563599     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0071     Document Type: Article

References (50)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147.
2. Reubinoff BE, Pera MF, Fong CY et al. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat Biotechnol 2000;18:399-404.
3. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
4. Koc ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-316.
5. Chen SL, Fang WW, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95.
6. Mazzini L, Fagioli F, Boccaletti R et al. Stem cell therapy in amyotrophic lateral sclerosis: A methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:158-161.
7. Koc ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222.
8. Lazarus HM, Koc ON, Devine SM et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11:389-398.
9. Ringden O. Introduction to graft-versus-host disease. Biol Blood Marrow Transplant 2005;11(2 suppl 2):17-20.
10. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-48.
11. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843.
12. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-3844.
13. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-3729.
14. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75:389-397.
15. Glennie S, Soeiro I, Dyson PJ et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821-2827.
16. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105:2214-2219.
17. Le Blanc K, Rasmusson I, Gotherstrom C et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004;60:307-315.
18. Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. STEM CELLS 2006;24:386-398.
19. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-1213.
20. Plumas J, Chaperot L, Richard MJ et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005;19:1597-1604.
21. Augello A, Tasso R, Negrini SM et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005;35:1482-1490.
22. Rao MS, Mattson MP. Stem cells and aging: Expanding the possibilities. Mech Ageing Dev 2001;122:713-734.
23. Fukuchi Y, Nakajima H, Sugiyama D et al. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. STEM CELLS 2004;22:649-658.
24. In't Anker PS, Scherjon SA, Kleijburg-van der KC et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. STEM CELLS 2004;22:1338-1345.
25. Yen BL, Huang HI, Chien CC et al. Isolation of multipotent cells from human term placenta. STEM CELLS 2005;23:3-9.
26. Wagner JE, Rosenthal J, Sweetman R et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: Analysis of engraftment and acute graft-versus-host disease. Blood 1996;88:795-802.
27. Miller JS, Tessmer-Tuck J, Pierson BA et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 1997;3:34-44.
28. Lazar GA, Dang W, Karki S et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006;103:4005-4010.
29. Gehling UM, Ergun S, Schumacher U et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95:3106-3112.
30. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-1193.
31. Hunt JS, Petroff MG, McIntire RH et al. HLA-G and immune tolerance in pregnancy. FASEB J 2005;19:681-693.
32. + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
33. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
34. Korholz D, Kunst D, Hempel L et al. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;19:691-695.
35. Dong H, Zhu G, Tamada K et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-1369.
36. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-1034.
37. Drukker M, Katchman H, Katz G et al. Human embryonic stem cells and their differentiated derivatives are less susceptible for immune rejection than adult cells. STEM CELLS 2006;24:221-229.
38. Drukker M, Katz G, Urbach A et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 2002;99:9864-9869.
39. Li L, Baroja ML, Majumdar A et al. Human embryonic stem cells possess immune-privileged properties. STEM CELLS 2004;22:448-456.
40. Gotherstrom C, Ringden O, Tammik C et al. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 2004;190:239-245.
41. Puissant B, Barreau C, Bourin P et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: Comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005;129:118-129.
42. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621.
43. + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005;90:516-525.
44. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
45. + regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004;200:1123-1134.
46. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
47. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-16.
48. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005;105:4120-4126.
49. Zhang M, Tang H, Guo Z et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol 2004;5:1124-1133.
50. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.